There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seattle Genetics (SGEN) and Adverum Biotechnologies (ADVM) with bullish sentiments.
Seattle Genetics (SGEN)
Leerink Partners analyst Andrew Berens maintained a Buy rating on Seattle Genetics today and set a price target of $167.00. The company’s shares closed last Tuesday at $166.20, close to its 52-week high of $175.64.
According to TipRanks.com, Berens is a 5-star analyst with an average return of 12.4% and a 67.6% success rate. Berens covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Deciphera Pharmaceuticals, and Zentalis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seattle Genetics with a $165.75 average price target, representing a -1.0% downside. In a report issued on June 22, J.P. Morgan also maintained a Buy rating on the stock with a $150.00 price target.
See today’s analyst top recommended stocks >>
Adverum Biotechnologies (ADVM)
In a report issued on June 27, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Adverum Biotechnologies, with a price target of $30.00. The company’s shares closed last Tuesday at $19.99.
According to TipRanks.com, Dolezal is a 4-star analyst with an average return of 52.2% and a 55.6% success rate. Dolezal covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Oyster Point Pharma, and Menlo Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adverum Biotechnologies with a $24.50 average price target, representing a 18.8% upside. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADVM:
